<DOC>
	<DOC>NCT01951898</DOC>
	<brief_summary>Montelukast is one of anti-inflammatory agents and a good controller for the patients with asthma. The hypothesis of the study is that the Montelukast will have airway anti-inflammatory effects and up-regulated regulatory T cells functions in asthma.</brief_summary>
	<brief_title>Effects of Montelukast on Airway Regulatory T Cells in Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>asthma mild status stable status nonsmoker Positive of airway hyperresponsiveness (MethacholinePC20&lt;16mg/mL) taken other asthmatic medications such as oral, injective, and inhaled steroids, leukotriene antagonists, oral, inhaled, and transdermal betaagonists, theophylline, antihistamine agents, antiIgE antibodies and long acting muscarinic receptor antagonists. respiratory tract infections within 4wks moderate to severe other organ disorders active malignancies past histories of side effects of leukotriene antagonists psychological disorders pregnancy or nursing</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>asthma</keyword>
	<keyword>regulatory T cells</keyword>
	<keyword>leukotriene antagonist</keyword>
</DOC>